Arrowhead Pharmaceuticals Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7398304".

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Monday, May, 3rd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.17. The biotechnology company had revenue of $32.81 million for the quarter, compared to analyst estimates of $39.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 23.64% and a negative net margin of 122.97%. Arrowhead Pharmaceuticals's revenue for the quarter was up 39.4% on a year-over-year basis.
View Arrowhead Pharmaceuticals' earnings history.

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARWR shares have increased by 139.4% and is now trading at $68.37.
View which stocks have been most impacted by COVID-19.

10 brokerages have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $34.00 to $110.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $86.45 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Arrowhead Pharmaceuticals include Shiseido (SSDOY), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN), Viatris (VTRS), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Dr. Reddy's Laboratories (RDY) and Ono Pharmaceutical (OPHLF).
View all of ARWR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%), Stratos Wealth Partners LTD. (0.01%), Fulton Bank N.A. (0.00%) and Sound Income Strategies LLC (0.00%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals.

ARWR stock was bought by a variety of institutional investors in the last quarter, including New Mexico Educational Retirement Board, Oregon Public Employees Retirement Fund, Stratos Wealth Partners LTD., Sound Income Strategies LLC, and Fulton Bank N.A..
View insider buying and selling activity for Arrowhead Pharmaceuticals or or view top insider-buying stocks.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARWR stock can currently be purchased for approximately $68.37.

Arrowhead Pharmaceuticals has a market capitalization of $7.12 billion and generates $87.99 million in revenue each year. The biotechnology company earns $-84,550,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

Arrowhead Pharmaceuticals employs 147,000 workers across the globe.

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at (626) 304-3400 or via email at [email protected]